Loading
Bria-IMT is an off-the-shelf immunotherapy made from laboratory-grown cancer cells, from BriaCell Therapeutics. It is being tested with a checkpoint inhibitor in a phase 3 trial in metastatic breast cancer.
Bria-IMT is the lead candidate of BriaCell Therapeutics, which describes it as a patented, off-the-shelf, cell-based targeted immunotherapy. It is being compared, with the checkpoint inhibitor retifanlimab, against treatment of the physician's choice in advanced metastatic breast cancer in the phase 3 trial NCT06072612 (BRIA-ABC), which plans 404 participants. BriaCell states that the FDA granted Bria-IMT Fast Track status.
Described by BriaCell Therapeutics as a patented, off-the-shelf, cell-based targeted immunotherapy, given with an immune checkpoint inhibitor. The ClinicalTrials.gov record of the phase 3 trial lists SV-BR-1-GM, cyclophosphamide and interferon infiltration of the inoculation site among the interventions of the Bria-IMT regimen.
1.Bria-IMT slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Bria-IMT" OR ABSTRACT:"Bria-IMT") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Bria-IMT, not a curated reading list.
Shares BriaCell Therapeutics, Off-the-shelf cancer vaccines and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/